Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have been given an average broker rating score of 1.63 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company.

Brokers have set a 12 month consensus target price of $20.67 for the company and are forecasting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Unum Therapeutics an industry rank of 80 out of 255 based on the ratings given to related companies.

Several research firms have recently commented on UMRX. Morgan Stanley upped their price objective on Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Unum Therapeutics in a research note on Tuesday, September 18th. Finally, Cowen restated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, September 17th.

In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $12.47, for a total value of $143,217.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

A number of hedge funds have recently modified their holdings of the business. Jennison Associates LLC increased its stake in Unum Therapeutics by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 935,307 shares of the company’s stock worth $13,305,000 after buying an additional 38,552 shares in the last quarter. Cowen Inc. purchased a new stake in Unum Therapeutics in the 2nd quarter worth $8,341,000. BlackRock Inc. purchased a new stake in Unum Therapeutics in the 2nd quarter worth $6,403,000. Point72 Asset Management L.P. purchased a new stake in Unum Therapeutics in the 1st quarter worth $3,599,000. Finally, Wasatch Advisors Inc. increased its stake in Unum Therapeutics by 5.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock worth $3,840,000 after buying an additional 13,525 shares in the last quarter. Institutional investors and hedge funds own 51.50% of the company’s stock.

Shares of NASDAQ:UMRX traded up $0.23 during midday trading on Wednesday, hitting $9.71. The company had a trading volume of 66,276 shares, compared to its average volume of 282,432. Unum Therapeutics has a 12-month low of $9.01 and a 12-month high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $2.45 million. Sell-side analysts expect that Unum Therapeutics will post -1.56 EPS for the current fiscal year.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Read More: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.